Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 444
- Registration Number
- NCT00000903
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic, San Rafael, California, United States
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 730
- Registration Number
- NCT00005918
- Locations
- 🇺🇸
The CORE Ctr, Chicago, Illinois, United States
🇺🇸Univ of Texas Med Branch, Galveston, Texas, United States
Tan tock Seng Hosp
A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 74
- Registration Number
- NCT00001122
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Univ of Texas Southwestern Med Ctr, Dallas, Texas, United States
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 288
- Registration Number
- NCT00001119
- Locations
- 🇺🇸
Seattle HIVNET, Seattle, Washington, United States
🇺🇸Univ of Washington, Seattle, Washington, United States
🇺🇸Univ of Minnesota, Minneapolis, Minnesota, United States
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
- Conditions
- HIV InfectionsLipodystrophy
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-02-28
- Target Recruit Count
- 342
- Registration Number
- NCT00021463
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Univ of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT00001087
- Locations
- 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Target Recruit Count
- 60
- Registration Number
- NCT00002227
- Locations
- 🇺🇸
The Whitman Walker Clinic, Washington, District of Columbia, United States
🇺🇸Richard Elion, Washington, District of Columbia, United States
🇺🇸Montrose Clinic, Houston, Texas, United States
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00002235
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸Pacific Oaks Med Group, Beverly Hills, California, United States
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002234
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
🇺🇸Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002419
- Locations
- 🇺🇸
Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pacific Oaks Med Group, Beverly Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.